BOEHRINGER-INGELHEIM
9.5.2023 14:36:33 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase AI-Driven Low Power FPGA Innovation at FPGA Horizons Conference29.9.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its participation in the upcoming FPGA Horizons conference, taking place on October 6 – 7, 2026 in London. As part of the conference’s technical program, Lattice will deliver a Tech Talk presentation and a hands-on workshop, and host a demo showcase focused on how its low power FPGA solutions are advancing AI at the edge. Who: Lattice Semiconductor What / When (GMT+2): Oct. 6, 2026 Demo showcase including Lattice Holoscan Sensor Bridge solution and Lattice Prompt™ AI-driven FPGA design tool Tech Talk (10:10 – 10:30 a.m.), Shaw Theater: Practical Security Fundamentals for FPGA Engineers Oct. 7, 2026 Workshop (1:30 – 4:40 p.m.), Hyde Park room Lattice Nexus™-based FPGA hands-on Lattice Prompt™ agentic AI workflow Where: FPGA Horizons Conference, Pullman London St Pancras, Euston Road, London NW1 FPGA Horizons is a UK-based conference for FPGA industry specialists. Supporting Res
NetApp Delivers Secure, Zero-Copy Data Activation for the Agentic Enterprise29.9.2026 19:30:00 CEST | Press release
Enterprises will be empowered to accelerate AI innovation to machine speed NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced new capabilities that enable enterprises to accelerate their adoption of agentic AI with secure, in-place, zero-copy data activation. The heterogeneous metadata capability of NetApp AI Data Engine (AIDE) helps organizations discover, understand, govern, and operationalize data where it lives, while an expanded integration with Commvault connects the NetApp Platform with Commvault recovery orchestration workflow to help customers detect attacks earlier and recover cleaner data faster. As AI agents move from experimentation into production, enterprise data infrastructure has become a critical business dependency. Agents can read, retrieve, and act on data at machine speed, but most enterprise data estates were built for human-paced workflows: fragmented across file, object, cloud, on-premises, and sovereign environments; governed
NetApp to Expand Partnership with SAP to Support SAP Cloud Infrastructure29.9.2026 19:30:00 CEST | Press release
NetApp to explore integrating NetApp capabilities with SAP Cloud Infrastructure storage architecture, to support secure, resilient, high-performance infrastructure for SAP and customer workloads NetApp, the intelligent Data Infrastructure company, today announced its intent to expand its long-standing partnership with SAP, with plans to explore deeper cloud-native integration of NetApp capabilities into SAP Cloud Infrastructure, SAP’s Infrastructure-as-a-Service platform. The NetApp Platform supports key elements of the SAP Cloud Infrastructure storage architecture, delivering reliable, highly available and high-performance file and block storage services. The NetApp Platform also provides built-in proactive data protection capabilities and data replication to support SAP’s global availability model. “SAP and NetApp share a long-standing commitment to empower the world’s most mission-critical enterprise environments,” said Álvaro Celis, Senior Vice President, Chief Commercial, Partner
NetApp Removes Storage Bottleneck for AI Factories29.9.2026 19:30:00 CEST | Press release
New architecture delivers fastest storage on the planet, designed to maximize GPU utilization and architected for up to 100 TB per second aggregate throughput NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced NetApp Novus™, the fastest storage on the planet designed for AI infrastructure providers operating large GPU environments. Built to support a zettabyte-scale file system, this next-generation architecture will allow AI factories to keep millions of GPUs continuously fed with data, maximizing the efficiency, utilization, and profitability of their investments. Neoclouds and GPU-as-a-Service providers are building AI factories at a scale that traditional storage architectures were never designed to support, creating bottlenecks that reduce GPU utilization and increase infrastructure costs. Under traditional architectures, GPU utilization can drop below 30 percent when AI factories cannot feed enough data to their GPUs to generate the results they
NetApp Empowers Enterprises to Build Anything, Anywhere29.9.2026 19:30:00 CEST | Press release
New hybrid multi-cloud capabilities remove borders between on-premises and cloud operations NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced new hybrid multi-cloud capabilities with autonomous controls to maximize enterprise flexibility and efficiency for any workload. Enterprises can now more easily adopt modern data strategies across on-premises and cloud environments leveraging new capabilities for consistent operations that account for sovereignty, governance, and controlled consumption. As enterprise applications and AI workloads increasingly span on-premises environments, public clouds, sovereign regions, and emerging AI Factory architectures, organizations need more than infrastructure flexibility. They need a consistent operating model that can keep pace with machine-speed demand while meeting requirements for governance, resilience, efficiency, and jurisdictional control. Traditional manual administration, fragmented tooling, and disconnecte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom